LumaBridge Announces Growth Capital Investment from Summit Partners

SAN ANTONIO AND BOSTON-(BUSINESS WIRE)–LumaBridge (formerly Cancer Insight), an oncology-focused clinical research organization (CRO), today announced a majority growth investment from global investor Summit Partners. The funding will help LumaBridge continues to build upon its work by offering best-in-class clinical trial solutions to support emerging biopharmaceutical companies working to develop life-changing immuno-oncology treatments.

LumaBridge was founded in 2014 by veterans Dr. George Peoples and Dan Hargrove to help develop new immunotherapies in the fight against cancer. Building on the founders’ 3 decades of combined experience in academic and military research, LumaBridge serves as a strategic partner to emerging biopharmaceutical and biotechnology companies, offering full outsourced clinical trial support throughout the clinical development timeline.

“Innovative therapies often come from unexpected places, but navigating complex clinical and regulatory pathways can be challenging,” said Dr. George Peoples, founder and chief medical officer of LumaBridge. “We created LumaBridge to provide expert support for the execution of clinical trials and ultimately to advance new immunotherapies that benefit patients.”

Read more: Cancer Insight is now LumaBridge

LumaBridge offers comprehensive CRO services, including clinical development strategy consulting as well as special capabilities in military research. In the 8 years since its founding, LumaBridge has made a significant impact in the advancement of immuno-oncology therapies, supporting a significant number of trials and projects for over 30 clients.

“Summit Partners has a long history of partnering with leading healthcare and life sciences companies, helping to accelerate their growth and development,” added Dave Boyle, CEO of LumaBridge. “We are excited to leverage Summit’s expertise and extensive resources as LumaBridge begins a new phase of growth and expands our ability to support more trials and bring more therapies to market.”

“The pool of clinical-stage immuno-oncology therapies is growing, as are the complexity, length and cost of these trials, fueling the need for outside services. In our experience, this is especially true among emerging biotech companies, which often lack the in-house resources to conduct trials,” said Mark de Laar, managing director of Summit Partners, who joined LumaBridge’s board of directors. “With a highly experienced and highly valued team, an extensive network of research sites, and robust clinical operations capabilities, we believe LumaBridge is strongly positioned to serve this important and growing need.” We are proud to partner with the LumaBridge team to support the company’s continued impact.”

About LumaBridge

LumaBridge is a dedicated clinical research organization (CRO) focused on creating innovative clinical trial solutions for biopharmaceutical companies. Founded in 2014 as Cancer Insight, the company offers customized clinical trial guidance, strategic partnership and personalized attention to each sponsor, accelerating the development of potential therapies.

LumaBridge builds on the success and experience of an experienced team led by George Peoples, MD, to help develop drugs, accelerate therapies for patients, and guide biopharmaceutical companies along clinical and regulatory pathways. As part of their comprehensive CRO services, LumaBridge offers consultation on trial design and clinical development strategy.

For more information, visit lumabridge.com.

About Summit Partners

Founded in 1984, Summit Partners is a global alternative investment firm that currently manages more than $35 billion of capital dedicated to growth capital, fixed income and public equity opportunities. Summit invests in growth sectors of the economy and has invested in more than 550 companies in healthcare, technology and other growth industries. Notable healthcare and life sciences companies supported by Summit include Advanced Cell Diagnostics, Clontech, Diagnostic Hybrids, Fortis Life Sciences, Integrated DNA Technologies, LakePharma and Viroclinics Biosciences. Summit maintains offices in North America and Europe and invests in companies worldwide. For more information, please see www.summitpartners.com or follow on LinkedIn.

Leave a Comment